## Gabriela Hernandez-Molina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1417055/publications.pdf

Version: 2024-02-01

85 papers 2,336 citations

304743 22 h-index 233421 45 g-index

90 all docs 90 docs citations

90 times ranked 2999 citing authors

#	Article	IF	CITATIONS
1	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.9	307
2	Exercise for osteoarthritis of the hip. The Cochrane Library, 2014, 2014, CD007912.	2.8	219
3	Effect of therapeutic exercise for hip osteoarthritis pain: Results of a metaâ€analysis. Arthritis and Rheumatism, 2008, 59, 1221-1228.	6.7	149
4	New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells, 2021, 10, 3592.	4.1	135
5	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjA¶gren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.9	132
6	The meaning of anti-Ro and anti-La antibodies in primary Sj $\tilde{A}$ ¶gren's syndrome. Autoimmunity Reviews, 2011, 10, 123-125.	5 <b>.</b> 8	106
7	Adipokine Contribution to the Pathogenesis of Osteoarthritis. Mediators of Inflammation, 2017, 2017, 1-26.	3.0	101
8	Central bone marrow lesions in symptomatic knee osteoarthritis and their relationship to anterior cruciate ligament tears and cartilage loss. Arthritis and Rheumatism, 2008, 58, 130-136.	6.7	69
9	Exercise for osteoarthritis of the hip. , 2009, , CD007912.		68
10	Novel autoantibodies in Sjögren's syndrome: A comprehensive review. Autoimmunity Reviews, 2019, 18, 192-198.	5.8	59
11	Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sjögren's syndrome. Rheumatology, 2020, 59, 2350-2359.	1.9	54
12	Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood, 2010, 116, 3058-3063.	1.4	52
13	Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercise in the management of hip osteoarthritis. Clinical Rehabilitation, 2016, 30, 935-946.	2.2	50
14	Peripheral regulatory cells immunophenotyping in Primary Sj $\tilde{A}$ ¶gren's Syndrome: a cross-sectional study. Arthritis Research and Therapy, 2013, 15, R68.	3.5	44
15	Similarities and Differences Between Primary and Secondary Sjögren's Syndrome. Journal of Rheumatology, 2010, 37, 800-808.	2.0	42
16	Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases. Rheumatology, 2011, 50, 1288-1292.	1.9	39
17	Autoimmune comorbidity in achalasia patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 203-208.	2.8	31
18	Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematous: A Cross-Sectional Study. Mediators of Inflammation, 2016, 2016, 1-15.	3.0	30

#	Article	lF	CITATIONS
19	X chromosome monosomy in primary and overlapping autoimmune diseases. Autoimmunity Reviews, 2012, 11, 301-304.	5.8	28
20	Clinimetric methods in Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 2013, 42, 627-639.	3.4	27
21	The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clinical and Experimental Rheumatology, 2013, 31, 382-8.	0.8	27
22	Coexistance of Amyloidosis and Primary Sjögren's Syndrome: An Overview. Current Rheumatology Reviews, 2018, 14, 231-238.	0.8	26
23	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology, 2021, 60, 4558-4567.	1.9	24
24	Histopathological environment besides the focus score in Sj $\tilde{A}$ ¶gren's syndrome. International Journal of Rheumatic Diseases, 2014, 17, 898-903.	1.9	23
25	Midfoot and forefoot osteoarthritis. Foot, 2014, 24, 128-134.	1.1	23
26	Elastographic ultrasound: an additional image tool in Sjögren's syndrome. International Journal of Rheumatic Diseases, 2018, 21, 1293-1300.	1.9	23
27	The role of the X chromosome in immunity and autoimmunity. Autoimmunity Reviews, 2007, 6, 218-222.	5.8	22
28	Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. Cytokine, 2019, 119, 95-112.	3.2	21
29	Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome. Thrombosis Research, 2019, 174, 141-147.	1.7	19
30	Gout in Renal Allograft Recipients According to the Pretransplant Hyperuricemic Status. Transplantation, 2008, 86, 1543-1547.	1.0	17
31	Markedly high salivary and lacrimal CXCL17 levels in primary Sjögren's syndrome. Joint Bone Spine, 2018, 85, 379-380.	1.6	17
32	Can nailfold videocapillaroscopy images be interpreted reliably by different observers? Results of an inter-reader and intra-reader exercise among rheumatologists with different experience in this field. Clinical Rheumatology, 2019, 38, 205-210.	2.2	17
33	Predicting Sjogren's syndrome in patients with recent-onset SLE. Rheumatology, 2013, 52, 1438-1442.	1.9	16
34	Absence of salivary CCL28 in primary Sjögren's syndrome. Rheumatology International, 2015, 35, 1431-1434.	3.0	16
35	IgG4-Related Disease. Journal of Clinical Rheumatology, 2022, 28, e596-e604.	0.9	16
36	Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjogren's syndrome in patients with systemic autoimmune diseases in the clinical setting. Rheumatology, 2015, 54, 441-448.	1.9	15

#	Article	IF	Citations
37	SARS-CoV-2 infection in patients with primary Sj $\tilde{A}$ ¶gren syndrome: characterization and outcomes of 51 patients. Rheumatology, 2021, 60, 2946-2957.	1.9	15
38	What is the meaning of ANCA positivity in IgG4-related disease?. Rheumatology, 2021, 60, 3845-3850.	1.9	14
39	PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases. JCI Insight, 2019, 4, .	5.0	14
40	Major salivary gland enlargement in IgG4-related disease is associated with multiorgan involvement and higher basal disease activity. Modern Rheumatology, 2020, 30, 172-177.	1.8	13
41	Pan-American League of Associations for Rheumatology (PANLAR) capillaroscopy study group consensus for the format and content of the report in capillaroscopy in rheumatology. Clinical Rheumatology, 2019, 38, 2327-2337.	2.2	12
42	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	1.9	12
43	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.8	12
44	Polyarticular arthritis secondary to Mycobacterium bovis infection: An unusual clinical presentation. Joint Bone Spine, 2007, 74, 107-109.	1.6	11
45	High-resolution HLA analysis of primary and secondary Sjögren's syndrome: a common immunogenetic background in Mexican patients. Rheumatology International, 2015, 35, 643-649.	3.0	11
46	Usefulness of IgA Anti-α-fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies as Substitute Immunological Criterion in Sjögren Syndrome with Negative Anti-SSA/SSB Antibodies. Journal of Rheumatology, 2016, 43, 1852-1857.	2.0	11
47	IgG4-related kidney disease: experience from a Mexican cohort. Clinical Rheumatology, 2020, 39, 3401-3408.	2.2	11
48	<i>HIF1A</i> (rs11549465) and <i>AKNA</i> (rs10817595) Gene Polymorphisms Are Associated with Primary Sjögren's Syndrome. BioMed Research International, 2017, 2017, 1-8.	1.9	10
49	Perioperative management of patients with antiphospholipid syndrome: a single-center experience. Rheumatology International, 2017, 37, 1159-1164.	3.0	9
50	MicroRNA Expression in Cutaneous Lupus: A New Window to Understand Its Pathogenesis. Mediators of Inflammation, 2019, 2019, 1-26.	3.0	9
51	Risk of Wnt/β-catenin signalling pathway gene polymorphisms in primary Sjögren's syndrome. Rheumatology, 2020, 59, 418-425.	1.9	9
52	Hyperviscosity in primary Sj $\tilde{A}$ ¶gren's syndrome: clinical implications. International Journal of Rheumatic Diseases, 2017, 20, 84-89.	1.9	8
53	Sarcoidosis: a single hospital-based study in a 24-year period. Revista De Investigacion Clinica, 2015, 67, 33-8.	0.4	8
54	Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clinical and Experimental Rheumatology, 2015, 33, 503-8.	0.8	8

#	Article	IF	CITATIONS
55	Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease. Scientific Reports, 2021, 11, 1832.	3.3	6
56	Main causes and risk factors for hospitalisation in patients with primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2015, 33, 721-5.	0.8	6
57	Chemokine tear levels in primary Sjögren's syndrome and their relationship with symptoms. International Ophthalmology, 2022, 42, 2355-2361.	1.4	5
58	Autoimmune Thyroid Disease in Primary Sjögren's Syndrome: Real-life Screening Practice and Clinical Outcomes. Current Rheumatology Reviews, 2022, 18, 272-277.	0.8	5
59	Factors influencing the EULAR Sjögren's Syndrome Patient-Reported Index in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 153-158.	0.8	5
60	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
61	Chronic Destructive Elbow Arthropathy Associated With Hydroxyapatite Crystals in a Patient With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2006, 12, 194-195.	0.9	3
62	Sjögren's syndrome and pancreatic affection. ReumatologÃa ClÃnica (English Edition), 2011, 7, 130-134.	0.3	3
63	Biopsy-proven renal involvement and prognosis in 13 hispanic patients with primary Sjögren syndrome. Medicina ClÃnica (English Edition), 2018, 150, 43-48.	0.2	3
64	Long-Term Effectiveness of Polymerized-Type I Collagen Intra-Articular Injections in Patients with Symptomatic Knee Osteoarthritis: Clinical and Radiographic Evaluation in a Cohort Study. Advances in Orthopedics, 2020, 2020, 1-9.	1.0	3
65	Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with mean platelet volume and hematological ratios. Thrombosis Research, 2021, 203, 12-17.	1.7	3
66	Clinical and Serological Features in Latin American IgG4-Related Disease Patients Differ According to Sex, Ethnicity, and Clinical Phenotype. Journal of Clinical Rheumatology, 2022, 28, 285-292.	0.9	3
67	Afección renal confirmada mediante biopsia y pronóstico en 13 pacientes hispanos con sÃndrome de Sjögren primario. Medicina ClÃnica, 2018, 150, 43-48.	0.6	2
68	Hughes–Stovin syndrome: an uncommon cause of pulmonary aneurysms. Rheumatology, 2020, 59, 2183-2184.	1.9	2
69	Persistent serological activity in primary Sjögren's syndrome. Clinical Rheumatology, 2020, 39, 919-923.	2.2	2
70	Omega-3 and omega-6 fatty acids in primary Sj $\tilde{A}$ ¶gren's syndrome: clinical meaning and association with inflammation. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 34-39.	0.8	2
71	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.8	2
72	Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option. Clinical Rheumatology, 2017, 36, 707-711.	2.2	1

#	Article	IF	Citations
73	Spontaneous cholecystocutaneous fistula as the presenting manifestation of IgG4-related disease. Surgery, 2022, 171, e17-e18.	1.9	1
74	$\hat{l}_{\pm}$ -enolase is an antigenic target in primary Sj $\tilde{A}$ ¶gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 29-35.	0.8	1
75	Performance of the 2016 ACR/EULAR SS classification criteria in patients with secondary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 130-133.	0.8	1
76	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sjögren's syndrome and systemic lupus erythematosus associated with Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 49-56.	0.8	1
77	Total body water and sicca symptoms in primary Sj $\tilde{A}$ gren's syndrome. Clinical and Experimental Rheumatology, 2022, , .	0.8	1
78	AB1241â€MOST PREVALENT COMORBIDITIES IN PRIMARY SJÃ-GREN'S SYNDROME IN A HISPANIC POPUL 2019, , .	ATION.,	0
79	Task Force Report on Non-criteria Manifestations: Thrombocytopenia., 2012,, 195-206.		0
80	Parotid gland swelling in primary Sjögren's syndrome: activity and other sialadenosis causes. Rheumatology, 2021, , .	1.9	0
81	Use and withdrawal of immunosuppressors in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 177-181.	0.8	0
82	Factors influencing the EULAR Sjögren's Syndrome Patient Reported Index in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
83	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sj $\tilde{A}$ ¶gren's syndrome and systemic lupus erythematosus associated with Sj $\tilde{A}$ ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
84	Post-COVID-19 syndrome in patients with primary Sj $\tilde{A}$ ¶gren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
85	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0